Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti-Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
ARTHRITIS & RHEUMATOLOGY（2019）
摘要
Abstract not available.
更多查看译文
关键词
active psoriatic arthritis,psoriatic arthritis,tildrakizumab,double-blind,placebo-controlled,multiple-dose,high-affinity
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要